The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Endothelin-1(ET-1) === Is a vasoconstrictor peptide released from vascular endothelial cells. At the cellular level, the balance between vasodilator (Nitric oxide) and vasoconstrictor (ET-1) actions determines the vascular response to insulin. So, high levels of ET-1, which achieved in insulin resistance states that includes patients that have T2DM or metabolic syndromes or they are obese, have inhibitory effect on nitric oxide production which results in low nitric oxide and heightened levels of ET-1. ET-1 activity is also enhanced secondary to abnormalities in vascular insulin signalling, In addition to its direct vasoconstrictor effects. Furthermore, ET-1 induces a reduction in insulin sensitivity and may take part in the development of the metabolic syndrome.
=== Notarial records === The primary source for compensating gaps in Parisian civil records is the "Minutier central des notaires de Paris." Established in 1932 under the law of March 14, 1928, this repository allows notaries in the Seine department to deposit records over 125 years old at the National Archives. It includes 100 million records, spanning from the late 15th century to the early 20th century, sourced from 122 Parisian notarial offices, numbered I to CXXII. Documents such as marriage contracts, wills, post-mortem inventories, and various other contracts offer insights into Parisian daily life since the late Middle Ages. While these documents help address gaps in civil records prior to 1860, they are also valuable for researchers studying local, social, demographic, or epidemiological history.
==== Brooders ==== Brooding species are most often ahermatypic (not reef-building) in areas of high current or wave action. Brooders release only sperm, which is negatively buoyant, sinking onto the waiting egg carriers that harbor unfertilized eggs for weeks. Synchronous spawning events sometimes occur even with these species. After fertilization, the corals release planula that are ready to settle.
Around 20–40% of those with coeliac disease experience non-responsive coeliac disease (NRCD), which is the continuation of symptoms despite elimination of gluten from their diets for at least 6 to 12 months. The most common cause of NRCD is unintentional gluten ingestion; however other conditions such as small intestinal bacterial overgrowth, giardiasis, disaccharide or FODMAP intolerance, Crohn's disease, fructose intolerance, microscopic colitis, pancreatic insufficiency, irritable bowel syndrome, and lactose intolerance can cause persistent symptoms or villous atrophy despite adhering to the GFD.
The term free describes how the graft is completely removed from the donor site rather than remaining attached via a pedicle. The term autogenous, from the Greek root auto- ("self"), describes how the individual who receives the graft is the same individual who provides the donor tissue. The connective tissue is generally taken from the hard palate, although it may be taken from other sites as well, such as the maxillary tuberosity area. Because the connective tissue for the graft is transplanted without the superficial epithelium from the donor site, it is termed subepithelial.
Sources: en.wikipedia.org
=== Hyperinsulinemic hypoglycemia === Some mutations have been found to enhance insulin secretion. Heterozygosity for gain of function mutations reduces the threshold glucose that triggers insulin release. This creates hypoglycemia of varying patterns, including transient or persistent congenital hyperinsulinism, or fasting or reactive hypoglycemia appearing at an older age. The most recent overview of GCK mutation that were observed in patients claimed 17 GCK mutations to cause hyperinsulinemic hypoglycemia. Homozygosity for gain of function mutations has not been found.
In bodybuilding and weight training, using drop sets (a.k.a. dropsets, descending sets, strip sets, the multi-poundage system the stripping method, triple-drops, down the rack, or running the rack) is a technique for continuing an exercise with a lower weight once muscle failure has been achieved at a higher weight. It is most often performed on weight machines because the weight is easier to switch, but it can also be performed with dumbbells and other free weights.
=== Traumatic === Frictional keratosis: This typically presents as white plaques on the oral mucosa due to mechanical trauma. When the cause of frictional keratosis is removed the white patch may resolve. Hyperplastic reactive lesions or nodular swellings: These occur in the oral mucosa due to low grade inflammation or trauma. They develop where the mucosa is subjected to chronic minor irritants, mechanical or infective. They most frequently occur on the buccal mucosa (inner cheek) along the occlusal line where the teeth meet and the gingivae (the mucosa which covers the gums); reactive nodules occurring here are specifically categorised as epulides instead of polyps. Also the alveolar ridge (the gum where the teeth erupt up from, or if missing, where they used to be) and the hard palate (roof of the mouth). The most common are fibrous nodules called fibroepithelial polyps and epulides. Other hyperplastic reactive hyperplastic lesions include those associated with dentures, and papillomas. However, they are all similar in cause and nature, the overproduction of the cells of the mucosa, primarily the epithelial cells, also fibrous myxoid and low inflamed tissue due to irritation. Fibroepithelial polyps are usually pale, firm to touch, and painless but further irritation can cause abrasion and then ulceration or bleeding. They are sometimes be called fibroma, such as leaf fibroma, a fibroepithelial polyp often occurring under a denture and appears flattened.
Suzetrigine, sold under the brand name Journavx, is an analgesic medication used in the treatment of moderate to severe acute pain. It is taken orally. Suzetrigine was developed by Vertex Pharmaceuticals. The most common adverse effects include itching, muscle spasms, increased blood level of creatine phosphokinase, and rash. Suzetrigine is a small-molecule non-opioid analgesic that works as a selective inhibitor of Nav1.8-dependent pain-signaling pathways in the peripheral nervous system. Nav1.8 channels are predominantly present in peripheral nociceptive neurons of the dorsal root ganglia. Suzetrigine inhibits pain signals before they reach the central nervous system and has no addictive potential. Suzetrigine was approved for medical use in the United States in January 2025. The US Food and Drug Administration considers it to be a first-in-class medication.
According to helium conservationists like Nobel laureate physicist Robert Coleman Richardson, writing in 2010, the free market price of helium has contributed to "wasteful" usage (e.g. for helium balloons). Prices in the 2000s had been lowered by the decision of the U.S. Congress to sell off the country's large helium stockpile by 2015. Richardson posited that the price of helium needed to be multiplied by 20 to eliminate excessive wasting of the gas. In a 2012 paper by Nuttall and colleagues titled "Stop squandering helium", they proposed to create an International Helium Agency that would build a sustainable helium market.
Sources: en.wikipedia.org
== Function == Like tendons, aponeuroses attached to pennate muscles can be stretched by the forces of muscular contraction, absorbing energy like a spring and returning it when they recoil to unloaded conditions. Also serving as an origin or insertion site for certain muscles e.g latissimus dorsi.
=== Drug delivery === Conventional drug delivery methods, such as systemic or topical delivery, are associated with many issues such as low solubility, off-target effects, and disadvantageous pharmacokinetics. Nanoparticles have been employed to increase solubility and target delivery of the drug to the desired tissue, increasing concentration of the drug at the site of action and decreasing drug concentration elsewhere, thereby increasing the efficacy of the drug and decreasing side effects. RGD has been employed to target nanoparticles containing drugs to specific cell types, especially cancer cells expressing integrin αvβ3. Many research groups utilize RGD to target the chemotherapeutic doxorubicin to cancer cells. Like other chemotherapeutics of its class, doxorubicin causes hair loss, nausea, vomiting, and myelosuppression, and can lead to cardiomyopathy and congestive heart failure. Clinically available Doxil utilizes liposomes to reduce accumulation of doxorubicin in myocardial tissue, thereby reducing cardiotoxicity. However, such nanoparticles rely on passive targeting of tumors by the EPR effect, which varies by patient and tumor type. Active targeting strategies aim to increase drug transport into cells to improve efficacy and counter multidrug resistance. In addition to doxorubicin, RGD-conjugated nanomaterials have been used to deliver the chemotherapeutics cisplatin, docetaxel, paclitaxel, 5-fluorouracil, and Gemcitabine to cancer cells. Such nanomaterials have also been used to deliver combination cytotoxic and vascular disrupting therapies.
== Meat == The most commonly consumed meat in China is pork. As of at least 2024, China is the second largest beef consuming market in the world. Steakhouses and hot pot restaurants serving beef are becoming increasingly popular in urban China. Chinese consumers particularly value freshly slaughtered beef.
Glover's Christian Scientists' Home." According to McClure's, there was a regular turnover of tenants and domestic staff, whom Eddy accused of stealing from the house; she blamed Richard Kennedy for using mesmerism to turn people against her. According to Peel, there was gossip about the attractive woman, the men who came and went, and whether she was engaged in witchcraft. She was hurt, he wrote, but made light of it: "Of course I believe in free love; I love everyone."
Fifth generation In the 1990s, the fifth generation of silicone-gel breast prosthesis contained a semi-solid silicone-gel with a viscosity that reduced the occurrence of filler leakage and the occurrence of the filler migration throughout the woman's body of any silicone-filler that leaked from the implant-pocket. The plastic surgery studies Experience with Anatomical, Soft Cohesive Silicone-gel Prosthesis in Cosmetic and Reconstructive Breast Implant Surgery (2004) and Cohesive Silicone-gel Breast Implants in Aesthetic and Reconstructive Breast Surgery (2005) reported lower incidence-rates of capsular contracture and lower incidence-rates of shell rupture, and rates of medical safety and technical efficacy greater than the rates of safety and efficacy of early-generation prosthetic breasts.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.